Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Nu Skin Enterprises director sells $24,640 in stock

Published 03/25/2024, 06:29 PM
Updated 03/25/2024, 06:29 PM
© Reuters.

In a recent transaction on March 25, Andrew D. Lipman, a board director of Nu Skin Enterprises, Inc. (NYSE:NUS), sold 2,000 shares of the company's stock. The sale was executed at a price of $12.32 per share, totaling $24,640.

This transaction was carried out in accordance with a prearranged trading plan that complies with the guidelines of Rule 10b5-1, which allows company insiders to set up a trading plan for selling stocks they own. Following this sale, Lipman's direct holdings in Nu Skin Enterprises stand at 27,225 shares.

The sale took place amidst the market's ongoing assessment of insider transactions, which are closely monitored as they can provide insights into a company's prospects. Nu Skin Enterprises, known for its personal care products and dietary supplements, has a presence in the wholesale proprietary drugs and druggists' sundries sector.

Investors and stakeholders of Nu Skin Enterprises keep an eye on such transactions to better understand the actions of the company's insiders and to gauge the stock's potential future direction. The details of the sale are now publicly available following the required regulatory filing.

InvestingPro Insights

Amidst the recent insider transaction by board director Andrew D. Lipman, Nu Skin Enterprises (NYSE:NUS) has shown several financial metrics that may be of interest to investors. With a market capitalization of $619.74 million and a high gross profit margin of 72.26% over the last twelve months as of Q4 2023, the company demonstrates a strong ability to retain earnings after the cost of goods sold.

One of the InvestingPro Tips for Nu Skin is the company's impressive gross profit margins, which align with the reported gross profit of $1422.98 million. This financial health indicator is crucial for stakeholders to consider, particularly when analyzing the company's operational efficiency and potential for profitability.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Another notable InvestingPro Tip is that Nu Skin has raised its dividend for 23 consecutive years, despite a recent decline in dividend growth of -84.42%. This consistent history of dividend payments may appeal to income-focused investors, especially considering the current dividend yield of 1.92%.

However, the company's stock has been under pressure, trading near its 52-week low and having experienced a significant price drop over the last year, with a one-year price total return of -66.06%. This may indicate a potential opportunity for investors to buy shares at a lower price point, which is further supported by the InvestingPro fair value estimation of $18.13, above the previous close price of $12.30.

For those seeking additional insights, there are many more InvestingPro Tips available on the platform, including expectations for net income growth this year and the stock's performance over various periods. To access these tips and more detailed analytics, visit https://www.investing.com/pro/NUS and use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.